MAGE-A3: an immunogenic target used in clinical practice.

abstract：:Hematopoietic stem cell transplantation is the treatment of choice for many hematologic malignancies and genetic diseases. However, viral infections continue to account for substantial post-transplant morbidity and mortality. While antiviral drugs are available against some viruses, they are associated with significan...

journal_title：Immunotherapy

authors： Tzannou I,Leen AM

更新日期：2015-01-01 00:00:00

abstract：:Aim: Assessment of safety, tolerability and changes in global clinical impression with an multiallergen immunotherapy treatment without dilutional effect in polyallergic patients. Patients & methods: This observational prospective study included patients with allergic rhinitis-rhinoconjunctivitis with or without asthm...

journal_title：Immunotherapy

authors： Alba P,Moreno V,Arias-Irigoyen J,Antón M,Parra A,Gómez-Fernández MC,Madariaga B,Martínez A,Begoña L

更新日期：2020-01-01 00:00:00

abstract：:Epstein-Barr virus-associated lymphoproliferative diseases (EBV-LPD) after hematopoietic stem cell transplantation or solid-organ transplantation remain a serious and potentially life-threatening complication. In the last decade, outcomes for EBV-LPD have significantly improved. Key to this success was the development...

journal_title：Immunotherapy

authors： Shaffer DR,Rooney CM,Gottschalk S

更新日期：2010-09-01 00:00:00

abstract：:It is now well established that the healthy bronchial tree contains a microbiome distinct from that of the upper respiratory tract and that the lung microbiome may be dysregulated in individuals with a chronic respiratory disease, such as asthma. In addition, after birth, gut microbes interact with the host tissue, es...

journal_title：Immunotherapy

authors： Pisi G,Fainardi V,Aiello M,Bertorelli G,Crisafulli E,Chetta A

更新日期：2017-11-01 00:00:00

abstract：:Bortezomib is an inhibitor of the ubiquitin-proteasome proteolytic pathway responsible for intracellular protein turnover. Cellular proteins controlled by this pathway represent a diverse group of potential therapeutic targets, particularly in cancer cells, which exploit this proteasomal pathway to promote their growt...

journal_title：Immunotherapy

authors： Pellom ST Jr,Dudimah DF,Thounaojam MC,Sayers TJ,Shanker A

更新日期：2015-01-01 00:00:00

abstract：:Background: The purpose of this study was to assess the effectiveness of immune checkpoint inhibitors (ICIs) in advanced urothelial carcinoma. Materials & methods: We selected seven cohorts of patients published in four clinical trials. The restricted mean survival time (RMST) was used to analyze survival curves, perf...

journal_title：Immunotherapy

authors： Rivano M,Cancanelli L,Spazio LD,Chiumente M,Mengato D,Messori A

更新日期：2021-02-01 00:00:00

abstract：:Aim: To compare daratumumab plus standard-of-care (SoC; bortezomib/thalidomide/dexamethasone [VTd]) and VTd alone with other SoC for transplant-eligible newly diagnosed multiple myeloma. Patients & methods: We conducted an unanchored matching-adjusted indirect comparison of progression-free and overall survival (PFS/O...

journal_title：Immunotherapy

authors： Moreau P,Hebraud B,Facon T,Leleu X,Hulin C,Hashim M,Hu Y,Caillot D,Benboubker L,Zweegman S,Merz M,Weisel K,Salwender H,Mai EK,Goldschmidt H,Bertsch U,Vanquickelberghe V,Kampfenkel T,Boer C,Krotneva S,Proskorovsky

更新日期：2021-02-01 00:00:00

abstract：:Although treatment options for castration-resistant prostate cancer (CRPC) have increased over the last decade, there remains a need for strategies that can provide durable disease control and long-term benefit. Recently, immunotherapy has emerged as a viable and attractive strategy for the treatment of CRPC. To date,...

journal_title：Immunotherapy

authors： Noguchi M,Koga N,Moriya F,Itoh K

更新日期：2016-01-01 00:00:00

abstract：:Background: Immunotherapy has revolutionized the treatment of cancer, but this has not come without a cost. Although immune checkpoint inhibitors are less toxic than conventional chemotherapy, they are associated with more frequent autoimmune side effects. Case presentation: We report a case of a patient with metastat...

journal_title：Immunotherapy

authors： Abushalha K,Abulaimoun S,Silberstein PT

更新日期：2020-06-01 00:00:00

abstract：:Myeloid-derived suppressor cells (MDSCs) are immature myeloid cells that infiltrate human and experimental tumors and strongly inhibit anticancer immune response directly or by inducing regulatory T-lymphocyte activity. Consequently, MDSCs are important actors of cancer-induced immune tolerance and a major obstacle to...

journal_title：Immunotherapy

authors： Martin F,Apetoh L,Ghiringhelli F

更新日期：2012-01-01 00:00:00

abstract：:Progressive multifocal leukoencephalopathy (PML) is a rare and severe complication of natalizumab therapy in patients with multiple sclerosis and it may be accompanied by immune reconstitution inflammatory syndrome (IRIS). Here, we describe a case of abnormally severe IRIS, which occurred 2 months after natalizumab-as...

journal_title：Immunotherapy

authors： Calvi A,De Riz M,Pietroboni AM,Ghezzi L,Maltese V,Arighi A,Fumagalli GG,Jacini F,Donelli C,Comi G,Galimberti D,Scarpini E

更新日期：2014-01-01 00:00:00

abstract：:Mycobacterium bovis bacille Calmette-Guerin (BCG) is one of the great success stories of immunotherapy as a treatment for superficial urothelial carcinoma of the bladder. Despite clinical effectiveness in over 50% of patients, the high incidence of local side effects and presence of nonresponders has led to efforts to...

journal_title：Immunotherapy

authors： Kresowik TP,Griffith TS

更新日期：2009-03-01 00:00:00

abstract：:Background: Severe pneumonia and acute respiratory distress syndrome (ARDS) due to COVID-19 is a challenge for nowadays medical practice. Although there is no clarity in the principal mechanism of lung damage and ARDS development, it has been suggested that one of the main reasons of this pathology is the hyperactivat...

journal_title：Immunotherapy

authors： Cala-García JD,Sierra-Bretón JD,Cavelier-Baiz JE,Faccini-Martínez ÁA,Pérez-Díaz CE

更新日期：2020-10-01 00:00:00

abstract：:Rituximab is a chimeric monoclonal antibody used to treat hematologic and autoimmune diseases by depleting CD20-expressing B cells. Patients may develop hypogammaglobulinemia following treatment, with some demonstrating failure of B-cell recovery. The true frequency of hypogammaglobulinemia and/or impaired B-cell reco...

journal_title：Immunotherapy

authors： Sacco KA,Abraham RS

更新日期：2018-06-01 00:00:00

abstract：:Breast cancer cells frequently express tumor-associated antigens that can elicit immune responses to eradicate cancer. Cancer-testis antigens (CTAs) are a group of tumor-associated antigens that might serve as ideal targets for cancer immunotherapy because of their cancer-restricted expression and robust immunogenicit...

journal_title：Immunotherapy

authors： Mahmoud AM

更新日期：2018-07-01 00:00:00

abstract：:The prognosis of high-risk neuroblastoma (NB) is still poor, in spite of aggressive multimodal treatment. Recently, adjuvant immunotherapy with anti-GD2 antibodies combined with IL-2 or GM-CSF has been shown to improve survival. Several other immunotherapy strategies proved efficacy in preclinical models of NB, includ...

journal_title：Immunotherapy

authors： Croce M,Corrias MV,Rigo V,Ferrini S

更新日期：2015-01-01 00:00:00

abstract：:TB is an infectious disease that still has an enormous impact on public health worldwide. With the continuous increasing epidemic of multidrug-resistant TB, new drugs and vaccines are urgently needed. In the last decade there has been a broad advance in the knowledge of innate immunity in TB. Together with the growing...

journal_title：Immunotherapy

authors： Rivas-Santiago CE,Hernández-Pando R,Rivas-Santiago B

更新日期：2013-10-01 00:00:00

abstract：:The era of active immunotherapy has now been successfully ushered into the clinical realm of advanced prostate cancer. The successful clinical trial development and US FDA approval of sipuleucel-T (Provenge®) has revamped the therapeutic paradigm for advanced prostate cancer. Nonetheless, physician and patient educati...

journal_title：Immunotherapy

authors： Shore ND

更新日期：2011-08-01 00:00:00

abstract：:In spite of the considerable successes that have been achieved in the treatment of chronic myeloid leukemia (CML), cure for the disease can only be obtained by the present means in a rather small minority of patients. During the past decade, considerable progress has been made in the understanding of the immunology of...

journal_title：Immunotherapy

authors： Vonka V

更新日期：2010-03-01 00:00:00

abstract：AIM:It is becoming apparent that emphysema is partly driven by self-reactive T cells inducing inflammatory damage. Thus, T cells become targets for therapy similar to other autoimmune diseases. Costimulatory blockade therapy targets disease-specific T cells, rendering them ineffective by blocking a necessary costimulat...

journal_title：Immunotherapy

authors： Newton AH,Danahy DB,Chan MA,Benedict SH

更新日期：2015-01-01 00:00:00

abstract：:The complex homeostasis of tissues is coordinated by the cytokine network and imbalances in this network may result in chronic immune disorders. Key specific cytokines, such as TNF-alpha, IFN-alpha, IL-4 or VEGF have been demonstrated to be overproduced or abnormally released in the microenvironment of pathologic tiss...

journal_title：Immunotherapy

authors： Bizzini B,Drouet B,Zagury D,Abitbol M,Burny A,Boissier MC

更新日期：2010-05-01 00:00:00

abstract：:Tumor immune evasion is one of the hallmarks of cancer, and expression of the B7 family of immune checkpoints (PD-L1, PD-L2, B7-H3, B7x and HHLA2) is one mechanism of immune evasion by tumors to suppress T-cell function. Antibodies blocking these interactions of B7-1/B7-2/CTLA-4 and PD-L1/PD-L2/PD-1 have had remarkabl...

journal_title：Immunotherapy

authors： Janakiram M,Pareek V,Cheng H,Narasimhulu DM,Zang X

更新日期：2016-06-01 00:00:00

abstract：AIMS:A therapeutic vaccine based on monocyte-derived dendritic cells (MDDCs) has been shown to represent a promising strategy for the treatment of cancer and viral infections. Here, we characterized the MDDCs used as an immunogen in a clinical trial for an anti-HIV-1 therapeutic vaccine. PATIENTS & METHODS:Monocytes o...

journal_title：Immunotherapy

authors： da Silva LT,da Silva WC,de Almeida A,da Silva Reis D,Santillo BT,Rigato PO,da Silva Duarte AJ,Oshiro TM

更新日期：2018-08-01 00:00:00

abstract：:Immunotherapy strategies for cancer are focused on inducing effective and specific cytotoxic responses mediated by CD8 T cells. On the other hand, immunosuppressive mechanisms induced by the tumor, such as the generation of tumor-specific CD4(+)CD25(+)FoxP3(+) Tregs, conspire against the efficacy of immunotherapies. I...

journal_title：Immunotherapy

authors： Muccioli M,Longstaff C,Benencia F

更新日期：2012-05-01 00:00:00

abstract：:In recent years, nanoparticulate-mediated drug delivery research has examined a full spectrum of nanoparticles that can be used in diagnostic and therapeutic cancer applications. A key aspect of this technology is in the potential to specifically target the nanoparticles to diseased cells using a range of molecules, i...

journal_title：Immunotherapy

authors： Fay F,Scott CJ

更新日期：2011-03-01 00:00:00

abstract：:Viral hemorrhagic fevers (VHFs) often cause high mortality with high infectivity, multiorgan failure, shock and hemorrhagic diathesis. Fibroblastic reticular cells (FRCs) within secondary lymphoid organs provide a supporting scaffold to T-lymphocyte areas. These cells regulate the movement of various immune cells and ...

journal_title：Immunotherapy

authors： Steele KE,Anderson AO,Mohamadzadeh M

更新日期：2009-03-01 00:00:00

abstract：AIM:Few studies have compared cluster immunotherapy and conventional administration regimens. The aim of this study was to establish the safety profile of these different regimens in patients with allergic respiratory diseases who received index-of-reactivity (IR)-standardized allergen extracts by the subcutaneous rout...

journal_title：Immunotherapy

authors： Quiralte J,Justicia JL,Cardona V,Dávila I,Moreno E,Ruiz B,García MA

更新日期：2013-12-01 00:00:00

abstract：:Although vaccination significantly reduces influenza severity, seasonal human influenza epidemics still cause more than 250,000 deaths annually. Vaccine efficacy is limited in high-risk populations such as infants, the elderly and immunosuppressed individuals. In the event of an influenza pandemic (such as the 2009 H1...

journal_title：Immunotherapy

authors： Ye J,Shao H,Perez DR

更新日期：2012-02-01 00:00:00

abstract：:Background: Progress in immunotherapy (IT) has shifted treatment paradigms for multiple malignancies. In March 2019, the combination of nab-paclitaxel and atezolizumab was approved by the US FDA for patients with PD-L1 positive metastatic triple-negative breast cancer based on positive results of the Impassion130 tria...

journal_title：Immunotherapy

authors： Philipovskiy A,Chambers K,Konstantinidis I,McCallum R,Corral J,Gaur S

更新日期：2020-12-01 00:00:00

abstract：:Sarcoidois is an inflammatory disease of unknown origin characterized by the abnormal accumulation of noncaseating granulomas at sites of disease activity in multiple organs throughout the body with a predilection for the lungs. Because the exact trigger that leads to disease activity is still under investigation, cur...

journal_title：Immunotherapy

authors： Celada LJ,Drake WP

更新日期：2015-01-01 00:00:00